Çağatay NUHOĞLU, Nevzat Aykut BAYRAK, Erkan YETMİŞ

Profilactic usage of N-acetyl cysteine in the treatment of tuberculosis in children may be effective in protection from hepatotoxicity: A case experience

Tuberculosis (TB) disease: Despite developed advanced diagnostic methods and new treatments, its frequency is increasing especially in developing countries and continues to cause death worldwide. Most of the drugs used in the disease process are hepatotoxic. These drugs are generally well tolerated, but their simultaneous use enhances each other’s hepatotoxic effect. The toxic hepatitis that develops during treatment, affects treatment compliance and treatment results can be fatal when it is not noticed, and adequate precautions are not taken. In our case, we wanted to report the protective effect of adding oral N-acetyl cysteine to quadruple (izoniazid, rifampicin, pyrazinamide, and ethambutol) TB treatment against recurrent hepatotoxicity that occurs during the treatment of TB.

PDF

___

1. Collu C, Fois A, Crivelli P, Tidore G, Fozza C, Sotgiu G, et al. A case-report of a pulmonary tuberculosis with lymphadenopathy mimicking a lymphoma. Int J Infect Dis 2018;70:38–41.
2. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. J Clin Exp Hepatol 2013;3(1):37–49.
3. Naqvi IH, Mahmood K, Talib A, Mahmood A. Antituberculosis drug-induced liver injury: An ignored fact, assessment of frequency, patterns, severity and risk factors. Open J Gastroenterol 2015;5(12):173–84.
4. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017;11(3):221–41.
5. Chalasani NP, Hayashi PH, Bonkovsky HI, Navarro VJ, Lee WM, Fontana RJ. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109(7):950–66.
6. Tahaoğlu K. Tüberkülozda Tedaviye Yanıtın Takibi ve İlaç yan Etkileri, Tüberkülin, Koruyucu Tedavi, Temaslı Muayenesi. Toraks Dernei Tüberküloz Çalışma Grubu. Toraks Derneği ikinci Yıllık Kongresi. Antalya 6-10 Mayıs 1998. p. 58–68.
7. Türkay C, Akbulut A. İlaca bağlı karaci¤er hasarı. In; Özden A, Fiahin B, Yılmaz U, Soykan İ, editors. Gastroenteroloji. Eylül: Türk Gastroentereoloji Vakfı; 2002. p. 601–4.
8. Kocabaş A. Tüberküloz tedavisinde sorunlar. Kocabaş A, editor. Tüberküloz kliniği ve kontrolü. Adana: Çukurova Üniversitesi Basımevi; 1991. p. 315–33.
9. Riska N. Hepatitis cases in isoniasid treated groups and in a control group. Bull Int Union Tuber 1976;51(1):203–8.
10. Singla R, Sharma SK, Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81– 6.
11. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharm 1996;31(1):47–64.
12. Baloğlu İ, Bahadır A. Tüberküloz tedavisi sırasında ortaya çıkan hepatotoksisite. Tüberküloz Toraks 1999;47:68–72.
13. Yurdakul AS, Çalışır HC, Taci N. Tüberküloz tedavisi sırasında gelişen hepatotoksisite. Toraks Derg 2003;4:16–20.
14. Singh JA, Garg PK, Thakur VS, Pade JN, Tandon RK. Anti -tuberculosis treatment- induced hepatotoxicity; role of predictive factors. Postgrad Med J 1995;71(836):359–62.
15. Madebo T, Lindtjorn B, Aukrust P, Berge RK. Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. Am J Clin Nutr 2003;78(1):117–22.
16. Muzembo BA, Mbendi NC, Ngatu NR, Suzuki T, Wada K, Ikeda S. Serum selenium levels in tuberculosis patients: A systematic review and meta-analysis. J Trace Elem Med Biol 2018;50:257–62.
17. Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011;6(7):e21836.
18. Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 2013;28(1):161–7.
19. Ejigu DA, Abay SM. N-acetyl cysteine as an adjunct in the treatment of tuberculosis. Tuberc Res Treatment 2020;2020:5907839.
20. Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, et al. Isoniazid and rifampicin-induced oxidative hepatic injury-protection by N-acetylcysteine. Hum Exp Toxicol 2000;19(9):517–22.
21. Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22(10):1235–8.
22. Bhilare NV, Dhaneshwar SS, Mahadik KR. Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation. World J Hepatol 2018;10(7):496–508.